Cleveland Clinic & Anixa submit IND for their breast cancer vaccine
Category: #health  By Saipriya Iyer  Date: 2020-11-25
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Cleveland Clinic & Anixa submit IND for their breast cancer vaccine

Anixa Biosciences, Inc., a renowned biotechnology firm primarily focused on the prevention and treatment of cancer as well as other infectious diseases, has reportedly announced that a new IND application for the company’s innovative breast cancer vaccine candidate has been submitted to the United States FDA.

The vaccine technology is being innovated by a Cleveland Clinic research team, which was led and supervised by Dr. Vincent Tuohy, from Lerner Research Institute, Cleveland Clinic. The biotechnology giant has a global and exclusive license to the said technology.

Moreover, the vaccine technology is being effectively developed at the Cleveland Clinic, and has received substantial funding from the United States Department of Defense. This funding is further anticipated to allow completion of the two separate Phase 1 clinical stage trials.

Dr. Tuohy, stated that if the trial data results showcase outcomes that are like the ones gotten from pre-clinical studies, the breast cancer vaccine might possibly have a substantial effect on breast cancer, which is a highly common malignancy seen in women.

Dr. Amit Kumar, President & CEO, Anixa Biosciences, stated that the firm is looking ahead to move this new technology into clinical development.

Dr. Kumar further added that if the human trial data is similar to the animal data, then the retired protein hypothesis of Dr. Tuohy would pave a novel way of preventing breast cancer and other kinds of tumors.

Dr. G. Thomas Budd, the Clinical Investigator for the trial, who is from Taussig Cancer Center, Cleveland Clinic, stated that the first clinical trial would be conducted in women that are diagnosed with early stage, high-risk triple negative breast cancer and are getting standard care at the Cleveland Clinic.

Dr. Budd further added that the expert team is looking ahead to start the Phase I trial as well as assess the diagnosed patients.

Source credit: https://www.prnewswire.com/news-releases/anixa-biosciences-and-cleveland-clinic-file-ind-application-for-breast-cancer-vaccine-301178420.html



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...